Showing 281-290 of 8423 results for "".
Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sImproving the After-Sun Treatment Market
https://practicaldermatology.com/series/c-suite-chats/improving-after-sun-treatment-market/29805/Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.Mechanisms for Food Allergy Initiation by Skin Pre-disposed to Atopic Dermatitis
https://practicaldermatology.com/issues/may-june-2025/mechanisms-for-food-allergy-initiation-by-skin-pre-disposed-to-atopic-dermatitis/35922/In this research report, we highlight a 2024 study by Gao et al. investigating the mechanisms underlying food allergy initiation in neonates susceptible to atopic dermatitis (AD).DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-3-year-clinical-data-lebrikizumab/28648/Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with moExosome Therapy: Explained
https://practicaldermatology.com/conferences/scale-2023/exosome-therapy-explained/20200/Jane Yoo, MD, explains exactly what exosomes are and highlights some current therapeutic uses for exosome therapy including treating hair loss and reducing redness after laser skin resurfacing.Is a Good Faith Estimate Required for a Filler or Neuromodulator Treatment?
https://practicaldermatology.com/topics/practice-management/is-a-good-faith-estimate-required-for-a-filler-or-neuromodulator-treatment/23852/The latest updates from CMS do not specifically mention aesthetics in reference to good faith estimates, but there are indications that some aesthetic and dermatology services will require them. What about an appointment for injectables?An Inside Look at How Incyte is Addressing Unmet Needs of Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/an-inside-look-at-how-incyte-is-addressing-unmet-needs-of-patients-with-atopic-dermatitis/20156/Ahmad Naim, Vice President of US Medical Affairs at Incyte, discusses the challenges around atopic dermatitis (AD) management and how Incyte is utilizing its expertise in immunology to address unmet needs for patients.What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thAre Exosomes the Next Big Thing?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/are-exosomes-the-next-big-thing/20090/Dr. Farris, co-founder (with Dr. Ted Lain) of the Science of Skincare Summit, summarizes key points from her recent article on exosomes and their potential applications for topical skincare? Are they the next big thing? Watch to find out!The Art of Patient Scheduling
https://practicaldermatology.com/topics/practice-management/the-art-of-patient-scheduling/23676/Is your patient scheduling system working as efficiently as possible? Put these five action items in place to ensure your practice is firing on all cylinders.